ME Therapeutics Holding (XCNQ:METX) Change In Inventory : C$0.00 Mil (TTM As of Feb. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Change In Inventory?

ME Therapeutics Holding's change in inventory for the quarter that ended in Feb. 2024 was C$0.00 Mil. It means ME Therapeutics Holding's inventory stayed the same from Nov. 2023 to Feb. 2024 .

ME Therapeutics Holding's change in inventory for the fiscal year that ended in Aug. 2023 was C$0.00 Mil. It means ME Therapeutics Holding's inventory stayed the same from Aug. 2022 to Aug. 2023 .

ME Therapeutics Holding's Total Inventories for the quarter that ended in Feb. 2024 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ME Therapeutics Holding Change In Inventory Historical Data

The historical data trend for ME Therapeutics Holding's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Change In Inventory Chart

ME Therapeutics Holding Annual Data

Trend

Aug22

Aug23

Change In Inventory

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24
Change In Inventory	Get a 7-Day Free Trial			-	-	-	-	-

ME Therapeutics Holding Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

ME Therapeutics Holding (XCNQ:METX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ME Therapeutics Holding's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ME Therapeutics Holding's Inventory Turnover for the quarter that ended in Feb. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ME Therapeutics Holding's Inventory to Revenue for the quarter that ended in Feb. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

ME Therapeutics Holding Change In Inventory Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

Q9T:Germany

Address

177 Robson Street, Vancouver, BC, CAN, V6B 0N3

Website

https://www.metherapeutics.com

ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines